BRIDGING THE GAP
Antibiotic resistance represents one of the greatest global threats to human health, causing approximately 700,000 deaths per year. Due to increasing rates of multidrug-resistance, deaths attributable to antibiotic resistant infections are projected to increase to 10 million annually by 2050, surpassing cancer as the leading cause of death worldwide.
The Britt Lab works at the interface of microbiology, immunology, and systems biology to discover novel therapeutic strategies for the mangement of “superbug” infections, using in vitro, ex vivo, and computational approaches. Our mission is to improve patient care, prevent harm, and preserve the miracle of antibiotic therapy.
Clinical Outcomes Research
multidrug-resistant Gram-negative infection
Vancomycin-resistant Enterococcus Infection
Staphylococcus aureus bacteremia
C. difficile infection
Human immunodeficiency virus Infection
Transplant infectious diseases
Microbiology and Immunology
IMMUNOMODULATION AND HOST-PATHOGEN INTERACTIONS IN SEPSIS